vTv Therapeutics Inc. (NASDAQ:VTVT) Stock Has Consensus Price Target of $55.83

Key Points

• Analysts maintain a “Moderate Buy” consensus on vTv Therapeutics, with six buy ratings, one strong buy, one hold, and one sell. The average 12-month price target is $55.83.
• Recent analyst actions were mixed: BTIG Research reaffirmed a $57 buy target, while HC Wainwright cut its target to $42 and Wall Street Zen downgraded the stock to sell.
• Shares opened at $25.17, well below their $44.00 52-week high, while the company reported a quarterly loss of $1.05 per share—worse than the $0.97 consensus estimate.

vTv Therapeutics Inc. (NASDAQ:VTVT - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $55.83.

Several analysts have weighed in on the stock. Wall Street Zen downgraded shares of vTv Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, October 24th. Weiss Ratings cut vTv Therapeutics from a "sell (d+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. BTIG Research reaffirmed a "buy" rating and set a $57.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, October 14th. HC Wainwright decreased their price objective on vTv Therapeutics from $45.00 to $42.00 and set a "buy" rating on the stock in a report on Thursday, August 6th. Finally, Zacks Research upgraded vTv Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Monday, September 7th.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in vTv Therapeutics stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of vTv Therapeutics Inc. (NASDAQ:VTVT - Free Report) by 114.4% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,360 shares of the biotechnology company's stock after buying an additional 2,860 shares during the quarter. China Universal Asset Management Co. Ltd.'s holdings in vTv Therapeutics were worth $161,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 17.51% of the company's stock.

vTv Therapeutics Stock Performance

Shares of NASDAQ:VTVT opened at $25.17 on Friday. vTv Therapeutics has a 52-week low of $20.04 and a 52-week high of $44.00. The firm has a fifty day moving average of $30.28 and a 200 day moving average of $33.57. The firm has a market capitalization of $99.17 million, a PE ratio of -23.75 and a beta of 0.21.

vTv Therapeutics (NASDAQ:VTVT - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.08). On average, sell-side analysts forecast that vTv Therapeutics will post -2.35 EPS for the current fiscal year.

vTv Therapeutics Company Profile

vTv Therapeutics Inc NASDAQ: VTVT is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.